Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.51 |
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28643401 | 0.92 | DPP4 (0.49) | NR1H2DPP4KDM4EPKMHPGD | |
| SCHEMBL28647908 | 0.92 | DPP4 (0.49) | NR1H2DPP4KDM4EPKMHPGD | |
| SCHEMBL28656767 | 0.87 | NR1H2 (0.54) | NR1H2DPP4KDM4EPKMHPGD | |
| SCHEMBL28645499 | 0.86 | NR1H2 (0.47) | NR1H2DPP4KDM4EPKMHPGD | |
| SCHEMBL23850138 | 0.86 | NR1H2 (0.47) | NR1H2DPP4KDM4EPKMHPGD | |
| SCHEMBL5574074 | 0.86 | HPGD (0.50) | NR1H2DPP4KDM4EPKMHPGD | |
| SCHEMBL515486 | 0.80 | NR1H2 (0.62) | NR1H2KDM4EPKMHPGDRECQL | |
| SCHEMBL621267 | 0.80 | NR1H2 (0.62) | NR1H2KDM4EPKMHPGDRECQL | |
| SCHEMBL514696 | 0.80 | NR1H2 (0.62) | NR1H2KDM4EPKMHPGDRECQL | |
| SCHEMBL190460 | 0.80 | NR1H2 (0.61) | NR1H2KDM4EPKMHPGDRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737470-A2 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | Zikani Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12552825-B2 | C10-alkylene substituted 13-membered macrolides and uses thereof | Zikani Therapeutics , Inc. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-3883647-B1 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | ZIKANI THERAPEUTICS INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20230093692-A1 | C10-Alkylene Substituted 13-Membered Macrolides and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2023-03-23 | — | — | US | disclosed |
| EP-3883647-A1 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | Zikani Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552825-B2 | C10-alkylene substituted 13-membered macrolides and uses thereof | MALT1, NR3C2, MRPL21 | NR1H2 12/4885DPP4 3608/4885KDM4E 4022/4885 |
| US-20230093692-A1 | C10-Alkylene Substituted 13-Membered Macrolides and Uses Thereof | RPS14, RPL17, RPN2 | NR1H2 278/4885DPP4 1733/4885KDM4E 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.